Previous 10 | Next 10 |
Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton Beach, Florida Ambulatory Surgery Centers (ASCs) Private equity-owned ophthalmology groups account for 14% of the U.S. based ASCs performing catarac...
2023-05-31 13:10:47 ET Gainers: Aridis Pharmaceuticals ( ARDS ) +130% . Marker Therapeutics MRKR +31% . SunCar Technology Group SDA +27% . T Stamp ( IDAI ) +25% . Inventiva ( IVA ) +19% . Eledon Pharmaceuticals ( ELDN ) +19% ...
2023-05-15 10:25:21 ET LENSAR, Inc. (LNSR) Q1 2023 Earnings Conference Call May 15, 2023, 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participant...
2023-05-15 07:18:12 ET LENSAR press release ( NASDAQ: LNSR ): Q1 GAAP EPS of -$0.40. Revenue of $8.25M (-11.7% Y/Y). For further details see: LENSAR GAAP EPS of -$0.40, revenue of $8.25M
Increased ALLY ® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2023 financial results will be ...
2023-03-16 09:33:06 ET LENSAR, Inc. (LNSR) Q4 2022 Earnings Call Transcript March 16, 2023 08:30 AM ET Company Participants Lee Roth - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants ...
2023-03-16 07:21:01 ET LENSAR press release ( NASDAQ: LNSR ): Q4 GAAP EPS of -$0.24 beats by $0.01 . Revenue of $10.2M (-9.1% Y/Y) beats by $0.2M . Earnings Before Interest, Taxes, Depreciation and Amortization for the quarter ended December 31, 2022 was ...
Installed ten ALLY ® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALL...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial r...
News, Short Squeeze, Breakout and More Instantly...
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global m...